Immunogen adherence and method of making and using same

ABSTRACT

A microbial adherence inhibitor in the form of fowl egg antibodies is disclosed, along with the method of making it and methods of using it. The inhibitor functions by substantially preventing the attachment of adherence of colony-forming immunogens in the respiratory tracts of host animals and humans. The inhibitor is made by inoculating female birds with the immunogen, harvesting the eggs which contain antibodies to the immunogen, and separating the yolk and albumin from the shells of the eggs. The yolk and albumin contents are administered to animals or human by distributing the contents directly or introducing the contents entrained in air.

CROSS REFERENCE TO RELATED APPLICATION

[0001] Applicant claims the benefit of U.S. Provisional ApplicationSerial No. 60/447,904 filed Feb. 19, 2003.

FIELD OF THE INVENTION

[0002] This invention is direct to microbial adherence inhibitors, inthe form of fowl egg antibodies, for substantially preventing theattachment or adherence of colony-forming illness-causing immunogens inrespiratory disease complex by inhibiting the immunogen to adhere to themucous membranes of animals including host food animals, high valuenonfood animals, zoological animals, companion animals, laboratoryanimals or humans, to the method of producing such adherence inhibitors,and to the methods of using such inhibitors.

BACKGROUND OF THE INVENTION

[0003] A group of microorganisms form a very complex interaction in therespiratory tract of animals. These animals can be dairy cattle, feedlotcattle, swine, and birds such as chickens and turkeys to name a few.Although the organisms can vary from animal group to animal group, theyare basically bacteria such as Pasteurellae, Mannhiemae, and Haemophilusgroups, Mycoplasma, and viruses of the respiratory groups such as bovinerespiratory syncytial virus (BRSV), bovine viral diarrhea (BVD),parainfluenza (PI₃), infectious bovine rhinotrocheitus (IBR), swineinfluenza, (H₁N₁,H₃N₂), fungi and parasites and combinations of thesame. These organisms are consisted as opportunistic respiratorypathogens that may reside in the upper respiratory tract of healthyanimals. Pasteurella and to a lesser extent Haemophilus and Mycoplasmaspecies may cause bovine respiratory disease complex (BRDC) in cattle bythe result of invasion of the lower respiratory tract after endogenousinjections of the nasopharynx. In dairy or feedlot cattle, a variety ofstressful situations such as shipment, weaning, viral infections, badweather, change in weather, movement in feedlots, poor nutrition, andovercrowding can impair the competence of the immune system and thephysical and immunological defenses of the animals. This allows greaternumbers of microorganisms to make the journey from the nasopaharyngealarea to the lower respiratory tract to the interior of the lungs. Thisleads to the pneumonic respiratory disease complex, which includes theshipping fever complex in cattle. Transmission between animals isusually by airborne droplets or by food or water contamination. Once themicroorganisms are established in the nasopharyngeal area, duringinspiration the aerosols can result in downward carriage of thebacterial into the lower respiratory tract. This allows the organisms toattach to the bronchi and alveolar cells and to multiply causingpneumonia. Lung infections can lead to lesions with no clinical signsbut lead to lower average daily gain. Animals can go off feed, becomevery ill rapidly and death can occur within hours. Morbidity can be veryhigh and once one animal becomes ill the rest of the herd are easier toinfect. This becomes a major concern for feedlots. Similar outbreaksoccur in swine herds and flocks of birds such as chickens and turkeys.Current live vaccines have had limited success in protecting the animalsagainst this complex. This may in part be due to the lack of immuneprotection in the nasopharyngal area. Although the group of respiratoryviruses can weaken the animals and decease the immunological response ofthe host, it is the bacterial strains (usually Mannhiema hemolytica orPasteurella multocida) that invade the lower respiratory tract leadingto bronchopneumonia (BRD) that lead to disease and death of the animal.In both shipping fever pneumonia and enzootic pneumonia in cattle, thefinal common denominator in both types of disease are the bacterialagents. Bovine respiratory disease (BRD) is the leading cause of diseaserelated loss in feedlots today. Financial losses attributed to BRDinclude mortality, medication, veterinary, and labor costs fortreatment. Average costs for one treatment average $8.80 per head.Heifers treated for BRD have lower morbidity scores by 37.9%. Animalsthat are never treated average $11.48 per head higher in net return. Theaverage daily gains differ between treated and untreated animals. Thenet profit averages $57.48 lower per head for treated animals. BRD hasbeen listed as causing 20.6% of all steer deaths in feedlots.

[0004] Porcine respiratory disease complex is a major and similar typeof disease affecting up to 90% of all swineherds. Mycoplasmahypopneumonia is the primary pathogen commonly associated with thecomplex secondary pathogens such as Pasteurella multocida types A and Dand can cause clinical signs of high fever or impaired growth.Combinations of these organisms can lead to both increase in severityand duration of pneumonia in swine. Porcine reproduction and respiratorysyndrome (PRRS) can be another major cause of pneumonia in swine. Thiscan lead to severe reproduction disease with only minimal dose ofvirulent PRRS stains. Common causation agents of Swine respiratorydisease can include PRRS virus, swine influenza (H1N1, H3N2) andMycoplasma hypopneumoniae along with Haemophilus parasuis, Haemophilussuis, Haemophilus planopneumonia, Pasteurella (Mannhiema) haemolyticaand Pasteurella multocida (types A & D). Estimating the total economicimpact on the health of these animals is difficult. Pneumonic lunglesions may cause poor respiratory health in herds and may affect up to70 percent of the pigs in a herd. Combinations of vaccinations forviruses and medication for bacteria are needed to help control theseproblems—timing of vaccination is always important. Medication must beapplied at the proper time to minimize costs and damage to the animals.

[0005] Organisms such as Mycoplasma hypopneumoniae can be a cause animportant chronic respiratory disease called “swine enzootic pneumonia”(SEP). This organism alone can produce severe pneumonia in swine andremains a significant threat to the swine industry.

[0006]Actinobacillus pleuropneumoniae causes “porcine pleuropneumoniae”,resulting in serious financial losses and death. Although vaccines havebeen developed, homologous protection has not been demonstrated. Duringthe past years, 14 serotypes and 2 biotypes have been identifiedworldwide. Both growing and finishing pigs must be vaccinated to protectherds.

[0007] The primary effect of respiratory disease in swineherds is seenin reduced feed intake that leads to impaired growth. This leads to lessuniformity in pigs, more mortality, less average daily gain, and lesspigs per litter. Producers report that almost 14.4% of all herdplacements develop respiratory disease. Costs increase for injectingvaccines and medication, and lower overall performance. Estimates havebeen made that reduced daily weight gain and antibiotics used to treatdisease cost the Swine industry 467 million dollars annually. Over 39%of all deaths in grower-finisher pigs had been attributed to respiratorydiseases in swine.

PRIOR ART

[0008] The production of avian egg antibody for the diagnosis ortreatment of specific conditions has been known. The production of avianegg antibody for the inhibition of organisms, specifically thecolonization of organisms, and the adherence and colonization ofillness-causing immunogens in the respiratory tracts of animals is notsuggested.

[0009] Representative prior art patents include the following:

[0010] Polson, U.S. Pat. No. 4,555,019

[0011] Stolle et al, U.S. Pat. No. 4,748,019

[0012] Tokoro, U.S. Pat. No. 5,080,895

[0013] Carroll, U.S. Pat. No. 5,196,193

[0014] Lee, U.S. Pat. No. 5,367,054

[0015] Coleman, U.S. Pat. No.5,585,098

[0016] Stolle et al, U.S. Pat. No. 5,753,268

[0017] Raun, U.S. Pat. No. 3,794,732, discusses the uses of polyesterantibiotics in ruminant rations to improve the utilization of feed inruminant animals. This specifically addresses the use of antibiotics inruminant animals as growth promotants.

[0018] Raun, U.S. Pat. No. 3,947,836, discusses the use of specificantibiotic compounds for ruminant feed utilization improvement whengiven orally to the animal. Specifically, the animal develops rumenfunction where more propionates in relation to acetates are producedthus improving feed utilization.

[0019] Ivy et al, U.S. Pat. No. 4,933,364, discusses an alternativeprocess for promoting growth and feed efficiency of food producingmammals. They propose the use of zinc antibiotic that can be added ininsoluble form to create a zinc antibiotic complex which enhances feedefficiency of food producing mammals. They reference two U.S. Pat. Nos.3,501,568 and 3,794,732, that cover monensin in great detail.

[0020] Other references on the use of additives such as monensin havementioned the need for wise application of these materials because theycan be toxic to some animals, such as horses. These antibiotics, whichare not approved for use in dairy cows, must be administered carefully.In addition, feed intake is initially reduced as monensin cannot beadded to molasses based supplements which are classic additives tocattle feeds. (Pate, F., “Ionophores Do Not Appear To Work In MolassesSupplements”, ONA Reports, November, 1966, 2 pages, Florida Cattlemanand Livestock Journal; Lona, R. P. et al, J. Anim. Sci. 75(1):2571-2579, 1979).

[0021] Polson, U.S. Pat. No. 4,550,019, is directed to the manufactureand use of fowl egg yolk antibodies for making immunologicalpreparations for the passive immunizations of animals, including humans,as immuno reagents for immunosorbitive processes and in particular forquantitative analytical tests, especially micro assays for diagnostic,pathological, forensic, and pharmacokinectic investigations.

[0022] Stolle et al, U.S. Pat. No. 4,748,018, is directed to a method ofpassive immunization of mammals using avian egg yolk antibody againstany of a variety of antigens using various methods of administrationunder various conditions and using various compositions incorporatingthe antibody, after first developing in the mammal a tolerance for theantibody.

[0023] Tokoro, U.S. Pat. No. 5,080,895, is directed to a specificantibody containing substance from eggs and method of production and usethereof for the treatment of infectious or other diseases, and asadditives in food for livestock and poultry, cosmetics, and medicines,and in the field of serodiagnosis. Although not explicitly stated, it isapparent that the use of the egg antibody in feeds is to provide an easymeans of oral administration of the antibody for the treatment ofintestinal infections in livestock or poultry.

[0024] Carroll, U.S. Pat. No. 5,196,193, and divisional U.S. Pat. No.5,443,976, are directed to anti-venom compositions containing horseantibody or avian egg yolk antibody for neutralizing snake, spider,scorpion or jelly fish venom.

[0025] Lee, U.S. Pat. No. 5,367,054, is directed to methods for largescale purification of egg immunoglobulins to lower somatic cell count inthe milk of lactating ruminants.

[0026] Stolle et al, U.S. Pat. No. 5,753,268, is directed to ananti-cholesterolemic egg vaccine and method for production and use as adietary supplement for the treatment of vascular disorders in humans andother animals.

SUMMARY OF THE INVENTION

[0027] Broadly stated, this invention is directed to a method for theproduction of a microbial adherence inhibitor for administration toanimals, such as host food animals, high value nonfood animals,zoological animals, companion animals, or humans to inhibit orsubstantially prevent the adherence of colony-forming immunogens in therespiratory tracts by first inoculating female birds, in or about toreach their egg laying age, with the particular target immunogen. Then,after a period of time sufficient to permit the production in the birdof antibody to the targeted immunogen, the eggs laid by the birds areharvested. The yolk and albumin antibody-containing contents of the eggsare separated from the shells. The antibody-containing contents of theeggs may be used directly, placed on an extender, or mixed with carriermaterial. The antibody can be incorporated into a liquid, mixed into alick tub, sprayed or squirted into the environment containing theanimals. The egg antibody adherence inhibiting material maybe stored orshipped for use as needed.

[0028] The egg contents incorporating the antibody specific to thetargeted immunogens are administered to the animals or humans bydistributing the antibody material directly or introducing antibodymaterial entrained in air. The material can be introduced into the nasalpharyngeal area of the animal by direct injection with a syringe orsprayed. The material can be administered with a squirt gun directly orintranasal inoculation. Aerosol mixtures can be made and administered asa mist over the heads and nostrils of the animals. Another alternativeis to mix the material with a carrier and administer as “top dressing”on feed. Special needs can be met by adding the material to water andletting the animals or humans drink the solution. The active materialcan be added to bulk licks or feed baskets for delivery. Gel-likemixtures can be made using common animal feed mixtures and pouring into“lick tubs” (feed additive bulk tubs). Other delivery systems can beadapted for delivery of the active material to the respiratory tract.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0029] The present invention is predicated on a method of inhibiting theability of colony forming microorganisms, such as Pasteurella(Mannhiema) haemolytica, P. multocida, and Haemophilus somnus, Swineinfluenza, Mycoplasma bovis or M. hypopneumoniae from adhering to themucous membranes and bronchi and alveolar cells of the respiratorytracts of animals thereby preventing colonization of the microorganisms.The failure of the microorganisms to colonize maintains theimmunological defenses of the animals when subjected to stress inducingenvironments. The result is that the animals have less pneumonicrespiratory diseases including shipping fever which cause high mortalityof infected animals (FIG. 1).

[0030] All mammals and birds provide similar types of protection whichallow for an immediate immune response in their very young offspringuntil they too acquire the ability to make the antibodies forthemselves. More specifically called passive antibody protection, thisdefense mechanism is passed to the young of mammals through theplacenta, the mother's milk, or through both. The young of birds,however, receive their passive antibody protection through the store ofantibodies placed in the eggs in which they develop from the embryonicstage. Birds, in particular, have the ability to “load up” their eggs asthey are formed, with a very large supply of antibodies concentratedover that which is present in the serum of the mother. In addition,avian antibodies are much more stable and resistant to inactivationthrough digestion than mammalian antibodies, especially under adverseconditions. Once immunized, the hen layers the unique IgY typesimmunoglobulins in the yolk while depositing the common chicken IgM andIgA immunoglobulins in the albumin. The albumin helps add resistance tothe whole egg preparations and helps protect the avian antibodies. Theavian IgY immunoglobulins in the yolk tightly bind to, coat, cover andobliterate adherins which attach themselves to their hosts. The albumin,IgM and IgA immunoglobulins increase binding in the mucous tissue of therespiratory tract of the antibody containing material which provideslonger sustaining effect of the antibody containing material. The IgMand IgA immunoglobulins have di-sulfide bonds that retain moleculestogether and provide larger antibody containing molecules. The largerantibody containing molecules are more effective in preventing adherenceof the targeted immunogen in the respiratory tract of the animal orhuman. Albumin is a protein that protects the activity of the IgYimmunoglobulins thereby increasing their active life in the respiratorytract. Furthermore, the large quantities of antibodies which are placedin eggs are much more exclusively those specific for the antigens towhich the mother has most recently been exposed to and challenged by.This all results in the eggs of birds being a most idea source for largequantities of economically produced highly specific and stableantibodies. While the invention is illustrated by the use of chickens toproduce avian antibody, other fowl including turkeys, ducks, geese,ostrich, Emu, pheasant, pigeon, quail, etc. or combination thereof, maybe used.

[0031] Specifically, groups are obtained of young hen chickens,typically Rhode Island Reds, White Leghoms, sex-linked hybrid crosses orother breeds suited to large egg size, high volume egg production andease of handling which are about to reach laying age, about 16-19 weeksfor chickens, on a schedule predetermined by the amount and timing offinal product desired resulting in a steady continuous productionstream. After a suitable period of isolation and acclimatization ofabout two to four weeks, each group will enter into an inoculationprogram using rehydrated proprietary preparations of specific antigens(immunogens) to which an antibody is desired. The cultures ofmicroorganisms may be obtained from commercial sources such as theAmerican Type Culture Collection (ATCC). The cultures may be used toisolate antigens. The antigens can be prepared as prepared immunogensand may be injected intramuscularly, but preferably injectedsubcutaneously. In approximately four to five weeks, the average eggcollected will contain copious amounts of the desired specific antibodyin a readily usable and stable form. The chickens may be reinoculatedwith the targeted immunogen throughout the egg laying period to maintainthe high antibody level.

[0032] Batches of eggs from predetermined groups of chickens arecracked, the contents are separated from the shells and mixed andpreferable pasteurized to eliminate potential pathogenic microorganismfrom the chicken and thus reduce potential contamination. Standard testprocedures are used, such as ELISA, agglutination, or the like are usedto the monitor the antibody activity. The typical batch is then blendedwith batches from groups of chickens at other average production levelsresulting in abundant standardized active ingredients. The egg antibodymicrobial inhibitor material may be stored and shipped on carriermaterials such as soy bean oil, boluses and/or tablets. Dependent on theneeds and specifications of the formulator and the final customer, thefinal antibody products may include some type of innocuous additive,such as dried whey or soy hulls, distillers grains, molasses, soy orrice husks or the like for formulation with feed ration. One eggproduced and processed by the above procedures will yield a productsufficiently active and stable to provide at least as many as 140 to 160doses of managed protection against specific microbial colonization.This method provides for the first time, an economical, safe andeffective means for controlling respiratory illness causing organisms inbeef cattle and dairy herds, swine, chickens, turkeys, companionanimals, high value nonfood animals, zoological animals and humans.

[0033] Immunogen adherence inhibitor and method of making and using sameproduces specific immunogens to the microbial species listed. Theimmunogens are used to immunize egg laying avian animals. The immunizedhen will lay eggs containing the specific antibodies of the IgM and IgAtype in the albumen and IgY type in the yolk. The eggs will be collectedand material from the whole cracked egg will be mixed in the properconcentration with a carrier mixture such as molasses, soy oil, DMSO,PBS buffer and Vitamin E solution. This solution is optimized so it canbe sprayed, squirted, injected intra-nasally, gelled, or used on topfeed and in lick tubs. The protective material may be sprayed over theanimals in the pens or feedlots during the feeding period usually oncein the morning and once in the evening. The number of sprayings isdetermined from testing. Since the material is non-toxic, it is given asneeded and as much as needed for a given pen. The preferred method is bydirect intra-nasal injection with a spray using ½ dose per nostril or acombination of direct nasal spray plus top feed, lick tub, squirtapplicators.

[0034] The product is an all natural preparation that contains specificavian antibodies to the targeted immunogens. These antibodies whenattached to the outer surface cell wall, adherin receptors, pilii orpilated structures and capsule, or viral capsid will not allow theorganism to attach to the mucous membranes. The microorganisms will notbe able to multiply or colonize. It will keep the microorganisms frommoving down the respiratory tract and eliminates the ability to causedisease in the lower respiratory tract. By spraying the material, themist will coat the nasopharynx and prevent the bacteria, viruses orother microorganisms from being spread in water droplets. The mist willalso coat the feed and water in the area, again blocking the ability ofthe organisms to spread from animal to animal. The method of theinvention provides for a substantial decrease in animal illness anddeath in feedlots and pens without the use of antibiotics.

[0035] By reducing respiratory organisms, one will decrease lunglesions, reduce secondary infection, improve daily gain, improveperformance, improve feed efficiency, and reduce costs. Controllingpneumonia in animals will improve growth performance and quality of lifeas well as lower potential spread of respiratory organisms. Similarexamples can be obtained in companion animals or humans. It is apparentthat many modifications and variations of this invention as hereinbeforeset forth may be made without departing from the spirit and scopethereof. The specific embodiments described are given by way of exampleonly and the invention is limited only by the terms of the appendedclaims.

[0036] The most successful colonizing microorganisms, bacteria, virusesand parasites, etc., have evolved a number of different types ofmolecules, referred to as “adherins” or “intimins”, on their surfaceswhich can very tightly stick to one or more types of specific moleculesthat are part of the host's various surfaces. The adhesion inhibitor isan avian antibody of extraordinary high specific activity which can verytightly bind to, coat, cover and obliterate these adherins which attachthemselves to their hosts with a lock and key type of fit to very uniquechemical structures. The avian IgY immunoglobulins in the yolk tightlybind to, coat, cover and obliterate adherins which attach themselves totheir hosts. The albumin, IgM and IgA immunoglobulins increase bindingin the mucous tissue of the respiratory tract of the antibody containingmaterial which provides longer sustaining effect of the antibodycontaining material. The IgM and IgA immunoglobulins have di-sulfidebonds that retain molecules together and provide larger antibodycontaining molecules. The larger antibody containing molecules are moreeffective in preventing adherence of the targeted immunogen in therespiratory tract of the animal or human. Albumin is a protein thatprotects the activity of the IgY immunoglobulins thereby increasingtheir active life in the respiratory tract. In addition to this directattack, components of the complement system included in most biologicalfluids, such as blood, lymph, saliva, tears and to some extentintestinal secretions, recognize an antibody attachment as triggers fortheir many types of defensive activities. Specific antibody attachmentand coating combined with the very likely mobilization of many othercellular defense systems, therefore, quickly culminating in the chemicalinactivation and ultimately the destruction of the targetedmicroorganism.

[0037] The invention is further illustrated by the following examples:

EXAMPLE 1 Selection of Egg Laying Avian Hens

[0038] The strain of egg laying hen may vary with needs and uses. Anyegg laying fowl hens may be immunized including chickens, turkeys,ducks, goose, pigeon, quail, ostrich, emus or any other fowl. The commonstrains of egg laying chickens are the preferred and are usuallyselected for the number of eggs laid per year, size of egg and ease ofhousing. Rhode Island Red, White Leghorn, and Red Sex Linked hybrids arethe animals of choice based on egg size (large to ex-large, 50-65 gm)and were used for the immunization schedules. The ease of handling theanimals and the size and uniformity of the eggs along with the number ofeggs laid per hen per year were observed. Although any avian egg layinghen could be used, for cost and ease of use these chickens proved towork the best. The White Leghorn, W98 Hybrid gave the most uniformityand greater number of eggs per animal. These animals produce a large toextra-large grade of egg (50-65 gm) and up to 300 eggs a year per hen.

EXAMPLE 2 Preparation of PM Antigen for Immunogen

[0039]Pasteurella Multicoda (ATCC 15743) was used as a model bacteria.The organism was isolated from cattle. The ATCC method for rehydrationof the stock was followed. The bacteria are re-hydrated in 1.0 ml ofTSB. Brain Heart Infusion (BHI, Acumedia) is used to stimulate the PMantigens on the bacterium. Stock TSB is inoculated into BHI Broth andincubated at 37° C. for 18-24 hours. This stimulates somatic andattachment antigens development on the bacteria. Flasks containing BHIBroth are inoculated with the BHI Broth culture. While stirring slowly,flasks are incubated at 37° C. Blood agar plates are streaked forisolation of colonies to confirm the morphology. Good growth is seenafter 22 hours. Flasks are combined and the material is harvested usingcentrifugation and sterile saline (0.9%) at approximately 3000 rpm for30 minutes. The harvest is collected in tubes. Density is checked usingspectrophotometer enumeration and McFarland nephelometer standards. Thematerial is diluted to approximately 1×10⁹ per ml. Four percent (4%)sodium deoxycholate (Difco) solution is added as a 1:1 ration withculture in 0.9% sterile saline (Herzberg, 1972) and stirred forapproximately 18 hours at room temperature (22° to 24° C.). The materialis centrifuged to remove whole cells. Supernatant is used as stock forPM antigen. Dry weight is determined at approximately 14.9 mg/ml. Theproduct is diluted in sterile PBS, pH 7.4 to 1 mg/ml for PM Immunogen.

EXAMPLE 3 Preparation of PH Antigen for Immunogen

[0040] Use stock P. Haemolytica (ATCC 14000) as stock for PH antigen.The organism was isolated from cattle. The ATCC method for rehydrationof the stock was followed. The bacteria are re-hydrated in 1.0 ml ofTSB. Brain Heart Infusion (BHI, Acumedia) is used to stimulate the PMantigens on the bacterium. Stock TSB is inoculated into BHI Broth andincubated at 37° C. for 18-24 hours. This stimulates somatic andattachment antigens development on the bacteria. Flasks containing BHIBroth are inoculated with the BHI Broth culture. While stirring slowly,flasks are incubated at 37° C. Good growth is seen after 22 hours. Bloodagar plates are streaked for isolation of colonies to confirm themorphology. Flasks are combined and the material is harvested usingcentrifugation and sterile saline (0.9%) at approximately 3000 rpm for30 minutes. The harvest is collected in tubes. Density is checked usingspectrophotometer enumeration and McFarland nephelometer standards. Thematerial is diluted to approximately 1×10⁹ per ml. Four percent (4%)sodium deoxycholate (Difco) solution is added as a 1:1 ration withculture in 0.9% sterile saline (Herzberg, 1972) and stirred forapproximately 18 hours at room temperature (22° to 24° C.). The materialis centrifuged to remove whole cells. Supernatant is used as stock forPH antigen. Dry weight is determined. The product is diluted in sterilePBS, pH 7.4 to 1 mg/ml for PH Immunogen.

EXAMPLE 4 Preparation of HS Antigen for Immunogen

[0041] Stock Haemophilus sommus (ATCC 43626) can be used as stockbacterial culture for HS antigen. The organism was isolated from cattle.The ATCC method for rehydration of the stock was followed. The bacteriaare re-hydrated in 1.0 ml of TSB. ATCC medium: 814 GC Medium is used tostimulate the HS antigens on the bacterium. Stock TSB is inoculated into814 GC Medium and incubated at 37° C. and 5% CO₂ for 18-24 hours. Thisstimulates somatic and attachment antigens development on the bacteria.Good growth is seen after 22-48 hours. Blood agar plates are streakedfor isolation of colonies to confirm the morphology. Flasks are combinedand the material is harvested using centrifugation and sterile saline(0.9%) at approximately 3000 rpm for 30 minutes. The harvest iscollected in tubes. Density is checked using spectrophotometerenumeration and McFarland nephelometer standards. The material isdiluted to approximately 1×10⁹ per ml. Four percent (4%) sodiumdeoxycholate (Difco) solution is added as a 1:1 ration with culture in0.9% sterile saline (Herzberg, 1972) and stirred for approximately 18hours at room temperature (22° to 24° C.). The material is centrifugedto remove whole cells. Supernatant is used as stock for HS antigen. Dryweight is determined. The product is diluted in sterile PBS, pH 7.4 to 1mg/ml for HS Immunogen.

EXAMPLE 5 Preparation of HSa Antigen for Immunogen

[0042] Use stock Haemophilus suis (ATCC 19417, H. parasuis) as stock forHSa antigen. The organism was isolated from swine. The ATCC method forrehydration of the stock was followed. The bacteria are re-hydrated in1.0 ml of TSB. ATCC Medium 5129: Haemophilus Test Medium is used tostimulate the HSa antigens on the bacterium. Stock TSB is inoculatedinto #5129 Broth and incubated at 37° C. for 24-48 hours. Thisstimulates somatic and attachment antigens development on the bacteria.Flasks containing #5129 Broth or plates containing #814 Medium areinoculated with Stock Broth culture. Flasks are incubated at 37° C. and5% CO₂. Good growth is seen after 48 hours. Blood agar plates arestreaked for isolation of colonies to confirm the morphology. Flasks arecombined and the material is harvested using centrifugation and sterilesaline (0.9%) at approximately 3000 rpm for 30 minutes. The harvest iscollected in tubes. Density is checked using spectrophotometerenumeration and McFarland nephelometer standards. The material isdiluted to approximately 1×10⁹per ml. Four percent (4%) sodiumdeoxycholate (Difco) solution is added as a 1:1 ration with culture in0.9% sterile saline (Herzberg, 1972) and stirred for approximately 18hours at room temperature (22° to 24° C.). The material is centrifugedto remove whole cells. Supernatant is used as stock for HSa antigen. Dryweight is determined. The product is diluted in sterile PBS, pH 7.4 to 1mg/ml for HSa Immunogen.

EXAMPLE 6 Preparation of ELISA Plates Using PH, PM, HS and HSa Antigensfor Monitoring Antibodies in Eggs Chickens and Feed

[0043] PH, PM, HS and HSa ELISA: Ninety-six well assay plate (flatbottom Costar) were coated using 100 μl/ml with various concentration ofantigens (10 μg-200 μg/ml) in carbonate buffer, ph 9.6. Plates wereincubated between 22° to 37° C. for up to 18 hours. The wells wereaspirated to prevent cross-contamination. The plates were blocked with390 μl/well of 0.5% BSA and incubated at 37° C. for 1 hour. Plates werecoated using alternative rows of positive or negative for controls.Plates were rinsed one time with wash buffer containing Tween™ 20. Onehundred microliters per well of diluted sample are added to wells induplicate wells, and incubated at 37° C. for one hour. Goat anti-chickenIgG conjugate with Horseradish peroxidase (Kirkegard and PerryLaboratories; 1:1000 to 1:3000) was added. After one hour incubation,the substrate (TMB, KPL) was added according to manufacturer'sinstructions and the reaction is stopped after 10 minutes with 0.1 Mphosphoric acid. Optical densities of the wells were determined inDynatech ELISA Reader at 450 nm and the information was recorded forfurther data analysis.

EXAMPLE 7 Analysis of Individual Eggs and Serum Over Time

[0044] Eggs were selected at various periods in the immunization periodfor monitoring antibody responses to the specific antigens. Selectedchickens were monitored at day 0 and continued on a monthly basis afterthe fourth month. The whole egg was collected from the shell and then a1 ml sample was taken. This sample was then extracted with buffer toanalyze the antibody content. The standard ELISA's for the PH, PM, HSand HSa immunogens were used for analysis. The negative readings weresubtracted from the OD readings.

EXAMPLE 8 Immunization of Chicken with PH Immunogen

[0045] Selected egg laying hens, White Leghoms, approximately 19 weeksold were injected with the stock PH immunogen. Four injections (500 μg,100 μg, 200 μg, and 250 μg) were given one week apart. A serum samplewas collected two weeks after the last initial injection. If boosterswere needed, 100 μg was given in each booster (every six months). Withinfour weeks, all hens produced excellent antibodies in the eggs. EILSA PHreadings averaged 1.00 OD for 1:10,000 dilution and 0.265 OD for1:50,000.

EXAMPLE 9 Immunization of Chicken with PM Immunogen

[0046] Selected egg laying hens, White Leghoms, approximately 19 weeksold were injected with the stock PM Immunogen. Four injections (500 μg,100 μg, 200 μg and 250 μg) were given one week apart. A serum sample wascollected two weeks after the last initial injection. If boosters wereneeded, 100 μg was given in each booster (every six months). Within fourweeks, all of the hens produced excellent antibodies in the eggs. EILSAPM readings averaged 1.42 OD for 1:10,000 dilution an 0.68 OD for1:50,000.

EXAMPLE 10 Immunization of Chicken with HS Immunogen

[0047] Selected egg laying hens, White Leghoms, approximately 19 weeksold were injected with the stock HS Immunogen. Four injections (500 μg,100 μg, 200 μg and 250 μg) were given one week apart. A serum sample wascollected two weeks after the last initial injection. If boosters wereneeded, 100 μg was given in each booster (every six months). Within fourweeks, all hens produced excellent antibodies in the eggs. EILSA HSreadings averaged 0.95 OD for 1:10,000 dilution an 0.250 OD for1:50,000.

EXAMPLE 11 Immunization of Chicken with HSa Immunogen

[0048] Selected egg laying hens, White Leghoms, approximately 19 weeksold were injected with the stock HS Immunogen. Four injections (500 μg,100 μg, 200 μg and 250 μg) were given one week apart. A serum sample wascollected two weeks after the last initial injection. If boosters wereneeded, 100 μg was given in each booster (every six months). Within fourweeks, all hens produced excellent antibodies in the eggs. EILSA HSareadings averaged 1.40 OD for 1:10,000 dilution an 0.576 OD for1:50,000.

EXAMPLE 12 Preparation of Stock Production Whole Egg Reagents

[0049] Selected hens were combined from all four immunogen groups to beused to produce production batches of whole egg reagents. Sterling (U.S.Pat. No. 5,753,228) presents and excellent review of uses for theselection of eggs and storage of the same. The eggs were randomized andshell removed. The whole egg is mixed well and pasteurized usingstandard conditions (60° C. (140° F.) for 3.5 minutes) Charley, H. andC. Weaver, 3^(rd) Edition, Foods: a scientific approach, Merril-PrenticeHall, p. 350, 1998). Once pasteurized, samples were tested for activityand store at 4° C. until dried or sprayed onto carriers. Samples of 250μl were analyzed. Examples of results for ELISAs are given:

[0050] Pasteurized Whole Egg: PM, PH, HS, HSa Mixtures ImmunogenDilution O.D PM 500 0.532 PM 2500 0.113 PH 500 0.466 PH 2500 0.115 HS500 0.338 HS 2500 0.128 HSa 500 0.588 HSa 2500 0.155

EXAMPLE 13 Analysis of Feed Additives for Antibody Activity

[0051] Samples of the material were collected from three batches. Thesamples were analyzed using the ELISA systems for PH, PM, HS and HSaimmunogens to monitor activity after pasteurizing and storage. Goodantibody response was recorded after the processing of the whole eggbatches. Data from three batches from example 20 method of production isgiven in the table below: Pasteurella Haemophilus Batch: LiquidImmunogen Signal/Noise Immunogen Signal/Noise Batch #1 0.347 5.32 0.1112.68 Batch #2 0.188 2.92 0.175 2.93 Batch #3 0.272 2.98 0.138 1.91

EXAMPLE 14 Testing on Feed Lot Cattle

[0052] A group of 222 calves from 2 different sources were shipped toIdaho. 109 calves were processed on day 0 and 113 processed on day 2.All calves received normal vaccination and processing which includesantibiotics designed to reduce disease stress and to increase averagedaily gain and feed efficiency. Half of the group received the materialby intranasal administration. Doses were directly injected into thenostril (1.5 cc/nostril: total 3 ml). The animals were tagged andmonitored for 35 days. All calves were housed in the same pen. The Testgroup had N=111 and the Control group had N=111. The following wasobserved: Controls (n = 111) Test (n = 111) Number Percent NumberPercent Pulled to 20 18 7 6 Hospital Treated for 19 17 7 6 RespiratoryDisease Deaths 3 3 0 0 Died from 2 2 0 0 Respiratory Disease Retreats 53

EXAMPLE 15 Testing of Feed Lot Cattle

[0053] A group of 165 sale barn calves were shipped in the middle ofsummer. Calves were processed on day 0 and on day 2. All calves receivednormal vaccination and processing which includes antibiotics designed toreduce disease stress and to increase average daily gain and feedefficiency. Half of the group received the material by Intranasaladministration. Doses were directly injected into the nostril (1.5cc/nostril: total 3 ml). The animals were tagged and monitored for 35days. Test group had N=82 and the Control group had N=83. The followingwas observed: Controls (n=83) Test (n=82) Controls (n = 83) Test (n =82) Number Percent Number Percent Pulled to 36 47 24 28 Hospital Treatedfor 36 43 22 25 Respiratory Disease Deaths 9 5 Died from 8 4 RespiratoryDisease Retreat 1X 14 12 Treated 2X 10 4 Treated 3X 4 3 Treated 4X 3 2Treated 5X 6 1 Treatment Cost $1,291.44 $ 796.51 Ave. Cost per $35.87  $ 30.64  Animal treated

EXAMPLE 16 Testing of Feed Lot Cattle

[0054] Two groups of calves were shipped to Idaho. 77 calves wereprocessed on day 0 from the first group. Half of the groups wereprocessed as Test (n=39) and other half as Control (n=38). The secondgroup of 78 were processed the same on day 2. All calves received normalvaccination, wormer, implants, and processing which includes antibioticsdesigned to reduce disease stress and to increase average daily gain andfeed efficiency. The Test group received the material by Intranasaladministration. Doses were directly injected into the nostril (1.5cc/nostril: total 3 ml). The animals were tagged and monitored for 35days. The Test group animals that were pulled to the hospital receivedbooster material along with normal treatment each time they went throughthe chute. The control cattle received only the normal treatment. TheTest group had N=77 and the Control group had N=78. The following wasobserved: Controls (n = 78) Test (n = 77) Number Percent Number PercentPulled to 18 23 13 17 Hospital Treated for 18 23 13 17 RespiratoryDisease Deaths 1 1 Died from 1 1 Respiratory Disease Retreat 1X 6 5Treated 2X 7 5 Treated 3X 3 3 Treated 4X 2 0 RES Realizers 1 2 RES Deads1 1 Death Rate 1.28 1.30 Treatment Cost $691.49 $ 478.59 Ave. Cost per$38.42  $ 36.81  Head Pulled Treatment $8.87  $6.22   Cost/Head in Pen

EXAMPLE 17 Testing of Weaned Calves

[0055] Four groups of calves were weaned at approximately 1000 to 2000calves per week. The calves were processed as small groups. All calvesreceived normal vaccination, wormer, implants, and processing whichincludes antibiotics designed to reduce disease stress and to increaseaverage daily gain and feed efficiency. The groups all received thematerial by Intranasal administration. Doses were directly injected intothe nostril (1.5 cc/nostril: total 3 ml). The animals were tagged andmonitored for 22 days. The group animals that were pulled to thehospital received booster material along with normal treatment each timethey went through the chute. Test group had N=5000. After 22 days only50 animals had been pulled for respiratory problems.

EXAMPLE 18 Testing Lick Tubs

[0056] The manufacturing process for the lick tubs is very simple andstraightforward. The manufacture of this example is done by addingprepared wet material and distillers condensed syrup to standard tubs toadjust the moisture content upward. We substituted dryer material andour liquid material to achieve the same moisture content as standardtubs that are currently being made to achieve a finished tub withsimilar properties.

[0057] The Total Batch Manufactured Lick Tub Example Includes theFollowing Ingredients: Dried Distillers Grains with Solubles (DDGS) 1170pounds Corn Gluten Meal 1365 pounds Wet Distillers Grains (wet coke) 465 pounds Vitamin and Mineral premix  750 pounds Magnesium Oxide  600pounds Mixed Antibody  540 liters Food grade Molasses  10 gallons MoldInhibitor   6 pounds

[0058] The DDGS, corn gluten meal, wet cake, mold inhibitor, premix andmagnesium oxide are placed in a 5-ton mixer truck and mixed for 5minutes. Then the material and Molasses are added. This is mixed for 30minutes. The resulting material weighs approximately 5,630 pounds. Thismixture is unloaded through a side discharge chute into twenty-eight200-pound plastic tubs and then compressed into a solid material. Thetubs are then cured for 48 hours into a very hard, bark brown productwith a somewhat yeasty, sweet odor (FIG. 4).

[0059] In one trial, one tub was placed near the cattle in a pen of onehundred ninety-seven 600-pound steers. The cattle in the test feedlotwere very interested in this material. They visit the tubs several timesa day. Consumption was about 7.7 grams/head/day. It is anticipated thatper head consumption would be somewhat higher if more tubs were placedin the pen.

EXAMPLE 19 Development of Top Dressing

[0060] One of the key preparations can be used for Top Dressing.Specific whole egg is collected from hens immunized with PH, PM, HS andHAs antigens in equal amounts for a total of 7-9 L. The whole eggmaterial is added to 2 L of PBS, pH 7.4, 4.5 L of molasses, and 4 L ofdistilled water. This is mixed well and preservatives such as food gradevitamin E, vanilla, sodium benzoate, potassium sorbate and sodiumcitrate are added to prevent microbial growth and extend shelf-life. Thetotal amount is 18 L. The mixture is stirred to get a homogenoussolution. The mixture is then pasteurized in a Food Pasteurizer from TheSchlueter Company. The material is cooled and stored at 4° C. untilused.

[0061] This material is poured on top of the feed as needed. It usuallyis distributed once every 7 days for a total of three applications.

EXAMPLE 20 Development of Material for Aerosol or Spray

[0062] One of the key preparations can be used for Aerosol or spray.Specific whole egg is collected from hens immunized with PH, PM, HS andHAs antigens in equal amounts for a total of 10 L. The whole eggmaterial is added to 6 L of PBS, pH 7.4 and 2 L of molasses. This ismixed well and preservatives such as food grade vitamin E, vanilla,sodium benzoate, potassium sorbate and sodium citrate are added toprevent microbial growth and extend shelf-life. The total amount is 18L. The mixture is stirred to get a homogenous solution. The mixture isthen pasteurized. The material is cooled and stored at 4° C. until used.

[0063] This material is sprayed directly over the heads of the animalsto form an aerosol. The material can also be poured into pressure gunssuch as squirt guns. Cowboys can carry these loaded guns out on therange or in the feedlot pens and deliver directly to the cattle asneeded. The material can be sprayed directly on the nose of theindividual animals as needed. This makes for a very versatile means ofapplication out on the range. It usually is distributed once every 7days for a total of three applications or as needed.

EXAMPLE 21 Animal Testing of Swine

[0064] A group of 77 feeder pigs approximately 60 lbs each were testedwith material made in Example 20 for Top Dressing. The animals weregiven the material as a top dressing on days 0, 7, 14 and 21. Theaverage losses on this farm over the last 5 years, due to respiratorycomplex, was 7.5% and over 30% were medicated during the first 21 daysof placement in pens. During the test period of 62 days, all animalswere in excellent condition and ahead of schedule with 0% losses and 0%medicated.

EXAMPLE 22 Animal Testing of Swine

[0065] A group of 80 feeder pigs approximately 50 lbs and considered therunts of the groups were tested with material made in Example 20 for TopDressing. The animals were given the material as a top dressing on days0, 7, 14 and 21. The average losses on this farm due to respiratorycomplex were 5% during the first 21 days and over 30% were medicated.These were the animals that had not done well in the past. This was theaverage for the farm over the last 5 years. During the test period of 55days, all animals were in very good condition and ahead of schedule andbetter than in the past with 1.25% losses and 0% medicated.

[0066] Any microorganism which colonizes the nasal pharyngeal region ofthe respiratory tract of its host must possess the capability ofsticking or adhering to the surface of the mucus membranes in order tomultiply. The respiratory pneumonia complex organisms such asPasteurella multocida, M. haemolytica, Haemophilus somnus, Swineinfluenza viruses and Mycoplasma bacteria are no exception to the rule.Other microorganisms from the fungi and parasite groups are included inorganisms that may cause respiratory problems in animals or humans. Theadherence inhibitor of this invention strongly interferes with adherenceand on a cumulative basis, thereby prevents the specific targetedmicroorganism from colonizing, and multiplying and moving down therespiratory tract and infecting the lower tract including the lungs.Through the vehicle of a simple nasal injection, spray, by top feed orlick tub, the product essentially supplies the host with specificantibody preparation designed not to cure any disease in the animal butmerely to dislodge any resident microorganism and to prevent theattachment of any newly introduced microorganism in the upperrespiratory tract. The adherence inhibitor has no direct effect on thehost itself, is all natural, leaves absolutely no undesirable residue inthe animals, and thus has no effect whatsoever on the ultimate foodproducts. In addition, since the microorganism is prevented frommultiplying, it will over time (for example 21-30 days) disappearthrough natural degradation from mucus of the animal, eliminating thesignificant potential source of contamination in the feedlot. Properlymanaged, the risk of cross contaminating other animals throughout thefeedlot is lowered and essentially eliminated. Similar applicationscould be developed for companion animals, zoological animals or nonfoodanimals or humans. They too have respiratory problems.

[0067] It is apparent that many modifications and variations of thisinvention as hereinbefore set forth may be made without departing fromthe spirit and scope thereof. The specific embodiments described aregiven by way of example only and the invention is limited only by theterms of the appended claims. The embodiments of the invention in whichan exclusive property or privilege is claimed as follows.

1. A microbial adherence inhibitor for administration to animals tosubstantially prevent the adherence of targeted colony-formingimmunogens in the respiratory tracts of said animals produced by themethod of: A. Inoculating female birds, in or about to reach their egglaying age, with a targeted colony-forming immunogen; B. Allowing aperiod of time sufficient to permit the production in the bird ofantibody-containing contents in the bird's eggs to the targetedcolony-forming immunogen; C. Harvesting the eggs laid by the birds; D.Separating the antibody-containing contents of said eggs from theshells.
 2. The microbial adherence inhibitor according to claim 1wherein: said colony-forming immunogen is one known to decrease ananimal's ability to utilize feed by causing respiratory disease.
 3. Themicrobial adherence inhibitor according to claim 2 wherein: saidtargeted colony-forming immunogen is from the class of respiratorybacteria including P. Multicoda, M. haemolytica, H. somnus, and H. suis.4. The microbial adherence inhibitor according to claim 2 wherein: saidtargeted colony-forming immunogen is from the class of respiratorybacteria uncluding Mycoplasma pleuropneumoniae, M. hypopneumoniae, andM. bovis.
 5. The method according to claim 1, wherein: theantibody-containing contents is derived from an egg from chicken,turkey, duck, goose, pheasant, emu, pigeon, ostrich, quail or anycombination thereof.
 6. The microbial adherence inhibitor according toclaim 1 wherein: said colony-forming immunogen is one known to causerespiratory illness in humans.
 7. The microbial adherence inhibitor ofclaim 1 including: mixing the separated antibody-containing contents ofsaid eggs with a carrier material.
 8. The microbial adherence inhibitorof claim 1 including: A. Mixing the separated antibody-containingcontents of said eggs; and B. Pasteurizing the mixed separatedantibody-containing contents of said eggs to eliminate potentialpathogenic microorganisms.
 9. The microbial adherence inhibitor of claim8 including: Storing the pasteurized mixture of separatedantibody-containing contents of said eggs on a carrier material.
 10. Themicrobial adherence inhibitor of claim 9 wherein: the carrier materialfrom a group of materials including soybean oil, molasses, distilleddried grains and beet pulp.
 11. The microbial adherence inhibitoraccording to claim 1 wherein: said targeted colony-forming immunogen isone known to cause respiratory illness in companion animals.
 12. Themicrobial adherence inhibitor according to claim 1 wherein: saidtargeted colony-forming immunogen is one known to cause respiratoryillness in high value nonfood animals, such as horses, zoologicalanimals, and laboratory animals.
 13. The microbial adherence inhibitoraccording to claim 1 wherein: said targeted colony-forming immunogensare from the class of respiratory viruses including swine influenza(H1N1, H3N2).
 14. The microbial adherence inhibitor according to claim 1wherein: said targeted colony-forming immunogens are from the class ofrespiratory viruses including bovine respiratory syncytial virus (BRSV),bovine viral diarrhea (BVD), bovine parainfluenza₃ (BPI₃ ), andinfectious bovine rhinotracheitis (IBR) viruses.
 15. A microbialadherence inhibitor for administration to food animals substantiallypreventing the adherence of targeted colony-forming immunogens in therespiratory tracts of said food animals comprising egg contentsincorporating antibody specific to said targeted colony-formingimmunogens.
 16. The microbial adherence inhibitor according to claim 15wherein said targeted colony-forming immunogens are know to decrease ananimal's ability to utilize feed thus lowering average daily gain. 17.The microbial adherence inhibitor according to claim 15 wherein: saidtargeted colony-forming immunogens are from the class of respiratoryviruses including swine influenza (H1N1, H3N2).
 18. The microbialadherence inhibitor according to claim 17 wherein: said targetedcolony-forming immunogens are known to cause respiratory complex inhumans.
 19. The microbial adherence inhibitor according to claim 15wherein: said targeted colony-forming immunogens are from the class ofrespiratory viruses including bovine respiratory syncytial virus (BRSV),bovine viral diarrhea (BVD), bovine parainfluenza₃ (BPI₃), andinfectious bovine rhinotracheitis (IBR) viruses.
 20. A microbialadherence inhibitor for promoting the growth of food animals bydecreasing the respiratory stress caused by the presence of acolony-forming immunogen in the respiratory tracts of said food animalsby inhibiting the ability of the colony-forming immunogen to adhere tothe respiratory tracts of food animals to reduce the ability of thecolony-forming immunogen to multiply, said colony-forming immunogen PRRSproduced by the method of: A. Inoculating female birds, in or about toreach their egg laying age, with P antigen from PRRS; B. Allowing aperiod of time sufficient to permit the production in the bird and eggslaid by the birds of antibody to P antigen from PRRS; C. Harvesting theeggs laid by the birds; D. Separating the antibody-containing contentsof said eggs from the shells.
 21. The microbial adherence inhibitoraccording to claim 20 wherein the separated antibody-containing contentsof said eggs is achieved by mixing with carrier material with theantibody-containing contents of said eggs.
 22. The microbial adherenceinhibitor according to claim 21 wherein carrier material is from a groupof materials including soybean oil, molasses, distilled dried grains andbeet pulp.
 23. The method according to claim 20, wherein theantibody-containing contents is derived from an egg from chicken,turkey, duck, goose, pheasant, Emu, pigeon, ostrich, quail or anycombination thereof.
 24. The microbial adherence inhibitor according toclaim 20 wherein; said colony-forming immunogen is one known to causerespiratory illness in companion animals.
 25. The microbial adherenceinhibitor according to claim 20 wherein: said colony-forming immunogenis one known to cause respiratory illness in high value nonfood animals,such as horses, zoological animals, and laboratory animals.
 26. A methodof decreasing animal respiratory illness by inhibiting the ability of atargeted colony-forming immunogen to adhere to the respiratory tract ofan animal to reduce the ability of the immunogen to multiply comprising:A. Inoculating female birds, in or about to reach their egg laying age,with a targeted colony-forming immunogen; B. Allowing a period Of timesufficient to permit the production in the bird of antibody-containingcontents in the bird's eggs to the targeted colony-forming immunogen; C.Harvesting the eggs laid by the birds; D. Separating the entire contentsof said harvested eggs from the egg shells; E. Mixing the separatedcontents of said harvested eggs; and F. Administering the mixedseparated contents of said harvested egg to said animal whereby theantibody to the targeted colony-forming immunogen inhibits adherence ofthe targeted colony-forming immunogen in the respiratory tract of theanimal.
 27. The method of claim 26 wherein: said targeted colony-formingimmunogen is from the class of respiratory bacteria including mycoplasmapieuropneumoniae, M. hypopneumoniae, and M. bovis.
 28. The method ofclaim 26 wherein: said targeted colony-forming immunogen is from theclass of respiratory bacteria including P. multicoda, M haemolytica, H.somnus, and H. suis.
 29. The microbial adherence inhibitor according toclaim 26 wherein: said targeted colony-forming immunogens are from theclass of respiratory viruses including bovine respiratory syncytialvirus (BRSV), bovine viral diarrhea (BVD), bovine parainfluenza₃ (BPI₃),and infectious bovine rhinotracheitis (IBR) viruses.
 30. The microbialadherence inhibitor according to claim 26 wherein: said targetedcolony-forming immunogens are from the class of respiratory virusesincluding swine influenza (H1N1, H3N2).
 31. The method of claim 26including: mixing the mixed separated contents of said harvested eggswith a carrier material.
 32. The method of claim 31 including:pasteurizing the mixture of the separated contents of said harvestedeggs to eliminate potential pathogenic microorganisms.
 33. The method ofclaim 32 including: storing the pasteurized mixture of the separatedcontents of said harvested eggs on a carrier material.
 34. The microbialadherence inhibitor according to claim 26 wherein: theantibody-containing contents of said eggs is administered to the animalby spraying or squirting material with the antibody-containing contentsof said eggs to animal feed.
 35. The microbial adherence inhibitoraccording to claim 34 wherein: the material is from a group of materialsincluding whey, molasses, PBS, and soy oil.
 36. The method of claim 26wherein: the antibody containing contents are administered by sprayingthe environment containing the animals with the antibody containingcontents.
 37. The method of claim 26 wherein: the antibody containingcontents are administered by intra-nasally injecting the animal with theantibody containing contents.
 38. The method of claim 26 wherein: saidtargeted colony-forming immunogen is from the class of respiratorybacteria including mycoplasma pieuropneumoniae, M. hypopneumoniae, andM. bovis.
 39. The method of claim 26 wherein: said targetedcolony-forming immunogen is from the class of respiratory bacteriaincluding P. multicoda, M. haemolytica, H. somnus, and H. suis.
 40. Themicrobial adherence inhibitor according to claim 26 wherein: saidtargeted colony-forming immunogens are from the class of respiratoryviruses including swine influenza (H1N1, H3N2).
 41. The microbialadherence inhibitor according to claim 26 wherein: said targetedcolony-forming immunogens are from the class of respiratory virusesincluding bovine respiratory syncytial virus (BRSV), bovine viraldiarrhea (BVD), bovine parainfluenza₃ (BPI₃), and infectious bovinerhinotracheitis (IBR) viruses.
 42. A method of producing a microbialadherence inhibitor for administration to a human to inhibit theadherence of targeted colony-forming immunogen in the respiratory tractsof the human comprising: A. Inoculating female birds, in or about toreach their egg laying age, with a targeted colony-forming immunogen; B.Allowing a period of time sufficient to permit the production in thebird of antibody-containing contents in the bird's eggs to the targetedcolony-forming immunogen; C. Harvesting the eggs laid by the birds; D.Separating the entire contents of said harvested eggs from the eggshells; and E. Mixing the separated contents of said harvested eggs. 43.The method of claim 42 wherein: said colony-forming immunogen is oneknown to cause respiratory illness in humans.
 44. The method of claim 42wherein: said targeted colony-forming immunogens are from the class ofrespiratory viruses including swine influenza (H1N1, H3N2).
 45. Themethod of claim 42 including: mixing the separated antibody containingcontents of said eggs with a carrier material.
 46. The method of claim42 including: A. Mixing the separated antibody-containing contents ofsaid eggs; and B. Pasteurizing the mixed separated antibody-containingcontents of said eggs to eliminate potential pathogenic microorganisms.47. The method of claim 46 including: Storing the pasteurized mixture ofseparated antibody-containing contents of said eggs on a carriermaterial.
 48. The method of claim 47 wherein: the carrier material froma group of materials including soybean oil, molasses, distilled driedgrains and beet pulp.